Irish Pharmacists Concerned by State Medicine Payments and Rising Costs

Irish pharmacists are primarily concerned about state payments for medicines, economic uncertainty, and rising business costs, according to a quarterly Pharmacy Pulse report by the Irish Pharmacy Union (IPU). Almost all pharmacies experienced increased operating costs over the past year, driven by higher wages, energy bills, IT infrastructure, and insurance.

Other concerns include reduced consumer spending (15 per cent), regulatory burdens, and losing key staff (both 10 per cent). Medicine shortages were cited by only 1 per cent as a significant business concern. New initiatives, such as pharmacies prescribing for common conditions, highlight their growing role in frontline healthcare.

Sales of medicines increased by 3.9 per cent in value in the 12 months to March, with prescription medicine sales jumping 9.5 per cent. Skin medications saw the fastest growth (up 256 per cent year-on-year), followed by diabetes drugs (22 per cent). Cancer therapies accounted for the largest share of sales at over 39 per cent, followed by diabetic medicines at 12.4 per cent. Over-the-counter sales were led by pain relief (over a quarter of sales) and cough, cold, and respiratory treatments (18.3 per cent).

Pierce Healy, chairman of the IPU’s pharmacy contractors committee, emphasized that rising costs and margin pressures threaten the sector's long-term sustainability. He stressed the need for support to ensure pharmacies can continue providing accessible, high-quality care, especially as the Community Pharmacy Agreement requires additional services and higher staffing costs.